316 related articles for article (PubMed ID: 34812550)
41. Aberrant splicing and defective mRNA production induced by somatic spliceosome mutations in myelodysplasia.
Shiozawa Y; Malcovati L; Gallì A; Sato-Otsubo A; Kataoka K; Sato Y; Watatani Y; Suzuki H; Yoshizato T; Yoshida K; Sanada M; Makishima H; Shiraishi Y; Chiba K; Hellström-Lindberg E; Miyano S; Ogawa S; Cazzola M
Nat Commun; 2018 Sep; 9(1):3649. PubMed ID: 30194306
[TBL] [Abstract][Full Text] [Related]
42. RBM17 Interacts with U2SURP and CHERP to Regulate Expression and Splicing of RNA-Processing Proteins.
De Maio A; Yalamanchili HK; Adamski CJ; Gennarino VA; Liu Z; Qin J; Jung SY; Richman R; Orr H; Zoghbi HY
Cell Rep; 2018 Oct; 25(3):726-736.e7. PubMed ID: 30332651
[TBL] [Abstract][Full Text] [Related]
43. How Is Precursor Messenger RNA Spliced by the Spliceosome?
Wan R; Bai R; Zhan X; Shi Y
Annu Rev Biochem; 2020 Jun; 89():333-358. PubMed ID: 31815536
[TBL] [Abstract][Full Text] [Related]
44. DHX15 is involved in SUGP1-mediated RNA missplicing by mutant SF3B1 in cancer.
Zhang J; Huang J; Xu K; Xing P; Huang Y; Liu Z; Tong L; Manley JL
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2216712119. PubMed ID: 36459648
[No Abstract] [Full Text] [Related]
45. Promoting spliceosome assembly for therapeutic intent.
Lu B; Abdel-Wahab O
Trends Pharmacol Sci; 2021 Dec; 42(12):981-983. PubMed ID: 34602305
[TBL] [Abstract][Full Text] [Related]
46. Modulation of SF3B1 in the pre-mRNA spliceosome induces a RIG-I-dependent type I IFN response.
Chang AY; Zhou YJ; Iyengar S; Pobiarzyn PW; Tishchenko P; Shah KM; Wheeler H; Wang YM; Loria PM; Loganzo F; Woo SR
J Biol Chem; 2021 Nov; 297(5):101277. PubMed ID: 34619148
[TBL] [Abstract][Full Text] [Related]
47. Characterization of the SF3B1-SUGP1 interface reveals how numerous cancer mutations cause mRNA missplicing.
Zhang J; Xie J; Huang J; Liu X; Xu R; Tholen J; Galej WP; Tong L; Manley JL; Liu Z
Genes Dev; 2023 Dec; 37(21-24):968-983. PubMed ID: 37977822
[TBL] [Abstract][Full Text] [Related]
48. Spliceosome Mutations Induce R Loop-Associated Sensitivity to ATR Inhibition in Myelodysplastic Syndromes.
Nguyen HD; Leong WY; Li W; Reddy PNG; Sullivan JD; Walter MJ; Zou L; Graubert TA
Cancer Res; 2018 Sep; 78(18):5363-5374. PubMed ID: 30054334
[TBL] [Abstract][Full Text] [Related]
49. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
50. Characteristics of patients with myelodysplastic neoplasm and spliceosome mutations.
Urrutia S; Li Z; Almanza E; Bataller A; Kanagal-Shamanna R; Senapati J; Sasaki K; Chien K; Montalban-Bravo G; DiNardo C; Borthakur G; Bueso-Ramos C; Pierce S; Kantarjian H; Garcia-Manero G
Leukemia; 2023 Jun; 37(6):1397-1400. PubMed ID: 37185307
[No Abstract] [Full Text] [Related]
51. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
52. Structures of SF3b1 reveal a dynamic Achilles heel of spliceosome assembly: Implications for cancer-associated abnormalities and drug discovery.
Maji D; Grossfield A; Kielkopf CL
Biochim Biophys Acta Gene Regul Mech; 2019; 1862(11-12):194440. PubMed ID: 31707043
[TBL] [Abstract][Full Text] [Related]
53. Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations.
Lee SC; North K; Kim E; Jang E; Obeng E; Lu SX; Liu B; Inoue D; Yoshimi A; Ki M; Yeo M; Zhang XJ; Kim MK; Cho H; Chung YR; Taylor J; Durham BH; Kim YJ; Pastore A; Monette S; Palacino J; Seiler M; Buonamici S; Smith PG; Ebert BL; Bradley RK; Abdel-Wahab O
Cancer Cell; 2018 Aug; 34(2):225-241.e8. PubMed ID: 30107174
[TBL] [Abstract][Full Text] [Related]
54. Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome.
Hong JY; Seo JY; Kim SH; Jung HA; Park S; Kim K; Jung CW; Kim JS; Park JS; Kim HJ; Jang JH
Anticancer Res; 2015 May; 35(5):3081-9. PubMed ID: 25964599
[TBL] [Abstract][Full Text] [Related]
55. GPATCH8 modulates mutant SF3B1 mis-splicing and pathogenicity in hematologic malignancies.
Benbarche S; Pineda JMB; Galvis LB; Biswas J; Liu B; Wang E; Zhang Q; Hogg SJ; Lyttle K; Dahi A; Lewis AM; Sarchi M; Rahman J; Fox N; Ai Y; Mehta S; Garippa R; Ortiz-Pacheco J; Li Z; Monetti M; Stanley RF; Doulatov S; Bradley RK; Abdel-Wahab O
Mol Cell; 2024 May; 84(10):1886-1903.e10. PubMed ID: 38688280
[TBL] [Abstract][Full Text] [Related]
56. Biological relevance of alternative splicing in hematologic malignancies.
Szelest M; Giannopoulos K
Mol Med; 2024 May; 30(1):62. PubMed ID: 38760666
[TBL] [Abstract][Full Text] [Related]
57. Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types.
Seiler M; Peng S; Agrawal AA; Palacino J; Teng T; Zhu P; Smith PG; ; Buonamici S; Yu L
Cell Rep; 2018 Apr; 23(1):282-296.e4. PubMed ID: 29617667
[TBL] [Abstract][Full Text] [Related]
58. The SF3B1
Guo J; Li C; Fang Q; Liu Y; Wang D; Chen Y; Xie W; Zhang Y
J Exp Clin Cancer Res; 2022 Jan; 41(1):26. PubMed ID: 35039052
[TBL] [Abstract][Full Text] [Related]
59. Aberrant splicing in neuroblastoma generates RNA-fusion transcripts and provides vulnerability to spliceosome inhibitors.
Shi Y; Yuan J; Rraklli V; Maxymovitz E; Cipullo M; Liu M; Li S; Westerlund I; Bedoya-Reina OC; Bullova P; Rorbach J; Juhlin CC; Stenman A; Larsson C; Kogner P; O'Sullivan MJ; Schlisio S; Holmberg J
Nucleic Acids Res; 2021 Mar; 49(5):2509-2521. PubMed ID: 33555349
[TBL] [Abstract][Full Text] [Related]
60. Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors.
Scott LM; Rebel VI
J Natl Cancer Inst; 2013 Oct; 105(20):1540-9. PubMed ID: 24052622
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
